Mylan/Agila Merger Requires Fourth Largest Divestiture In Generic Industry
This article was originally published in The Pink Sheet Daily
FTC mandates that the two companies sell off 11 generic injectable drugs as a condition for allowing their merger; Intas, Sagent, JHP Pharmaceuticals and Gland Pharma are to acquire the products.
You may also be interested in...
The required divestitures are quite significant relative to the size of the transaction: this is the second-largest divesture, but only the fifth-largest merger of generic firms.
FDA guidances have provided ‘major step forward’ for use of social media data, Roche researcher notes. Agency staffer offers checklist for collecting patient experience data in this realm.
Agency staff note hurdles in obtaining evidence outlined in FDA’s patient-focused drug development guidance to support regulatory decision-making.